CUT'HIVAC
Cutaneous and Mucosal HIV Vaccination
| Coordinatore | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
Organization address
address: Place Jussieu 4 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 15˙439˙854 € |
| EC contributo | 11˙929˙250 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6
Organization address
address: Place Jussieu 4 contact info |
FR (PARIS) | coordinator | 1˙963˙463.20 |
| 2 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 2˙963˙186.20 |
| 3 |
FIT BIOTECH OY
Organization address
address: Biokatu 8 contact info |
FI (Tampere) | participant | 1˙648˙460.00 |
| 4 |
UNIVERSITAET REGENSBURG
Organization address
address: UNIVERSITAETSSTRASSE 31 contact info |
DE (REGENSBURG) | participant | 1˙270˙801.00 |
| 5 |
FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA
Organization address
address: CARRETERA DE CANYET contact info |
ES (BARCELONA) | participant | 974˙680.00 |
| 6 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 759˙760.00 |
| 7 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 621˙400.00 |
| 8 |
NOVAMEN SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 368˙306.00 |
| 9 |
ASOCIACION CIVIL IMPACTA SALUD Y EDUCACION
Organization address
address: AVENIDA ALMIRANTE MIGUEL GRAU 1010 contact info |
PE (LIMA) | participant | 282˙338.00 |
| 10 |
Nome Ente NON disponibile
Organization address
address: Avenida Eduardo Mondlane 1008 contact info |
MZ (Maputo) | participant | 241˙334.00 |
| 11 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 239˙822.86 |
| 12 |
Investigaciones Medicas en Salud
Organization address
address: Jose de la Torre Ugarte 166 contact info |
PE (Lima) | participant | 130˙899.74 |
| 13 |
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
Organization address
address: Cranmer Terrace contact info |
UK (LONDON) | participant | 119˙326.50 |
| 14 |
GENEART AG
Organization address
address: Josef-Engert-Strasse 11 contact info |
DE (REGENSBURG) | participant | 109˙599.00 |
| 15 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 108˙095.64 |
| 16 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 96˙811.04 |
| 17 |
OBJECTIF RECHERCHE VACCIN SIDA
Organization address
address: BOULEVARD DE L HOPITAL 47-83 contact info |
FR (Paris) | participant | 30˙966.60 |
| 18 |
ACIES Consulting Group SAS
Organization address
city: LYON contact info |
FR (LYON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUT’HIVAC consortium gathers knowledge’s and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUT’HIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU® candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUT’HIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.'